Extension of Series A Supports Operations Expansion and Increased Promotion
We are pleased to announce that ExpressCells has completed an extension of its Series A financing round. $590,500 was raised in this Series A2 round from both existing and new investors. This round was oversubscribed by 18%.
Our new investors in ExpressCells include the MIT Alumni Angels of Northern California, the Orange County Chapter of Tech Coast Angels, and the Berkeley Angel Network. Existing investors who also invested in this round include the Rowan Innovation Venture Fund, the Central Texas Angel Network, Robin Hood Ventures, and Ben Franklin Technology Partners of Southeastern Pennsylvania. Continue reading press release online or click below to download.
Better Knock-ins, Better Cell Lines, Better Science
ExpressCells leverages proprietary gene-editing tools to customize human cell lines for drug discovery, toxicology, and other biologic research.